Subramanian Sankar - 03 Mar 2025 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role: Senior VP, Product Development
Signature: /s/ Mathew B. Murphy, as Attorney-in-Fact
Issuer symbol: NAUT
Transactions as of: 03 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2025, 16:51:29 UTC
Previous filing: 05 Mar 2024
Next filing: 04 Mar 2026
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAUT	Stock Option (Right to Buy)	Award	$0	+160,000		$0.000000	160,000	03 Mar 2025	Common Stock	160,000	$1.24	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025.

Content

25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025.